Device-associated Infection Rates, Mortality, Length of Stay and Bacterial Resistance in Intensive Care Units in Ecuador: International Nosocomial Infection Control Consortium's Findings
Overview
Authors
Affiliations
Aim: To report the results of the International Nosocomial Infection Control Consortium (INICC) study conducted in Quito, Ecuador.
Methods: A device-associated healthcare-acquired infection (DA-HAI) prospective surveillance study conducted from October 2013 to January 2015 in 2 adult intensive care units (ICUs) from 2 hospitals using the United States Centers for Disease Control/National Healthcare Safety Network (CDC/NHSN) definitions and INICC methods.
Results: We followed 776 ICU patients for 4818 bed-days. The central line-associated bloodstream infection (CLABSI) rate was 6.5 per 1000 central line (CL)-days, the ventilator-associated pneumonia (VAP) rate was 44.3 per 1000 mechanical ventilator (MV)-days, and the catheter-associated urinary tract infection (CAUTI) rate was 5.7 per 1000 urinary catheter (UC)-days. CLABSI and CAUTI rates in our ICUs were similar to INICC rates [4.9 (CLABSI) and 5.3 (CAUTI)] and higher than NHSN rates [0.8 (CLABSI) and 1.3 (CAUTI)] - although device use ratios for CL and UC were higher than INICC and CDC/NSHN's ratios. By contrast, despite the VAP rate was higher than INICC (16.5) and NHSN's rates (1.1), MV DUR was lower in our ICUs. Resistance of to imipenem and meropenem was 75.0%, and of to ciprofloxacin and piperacillin-tazobactam was higher than 72.7%, all them higher than CDC/NHSN rates. Excess length of stay was 7.4 d for patients with CLABSI, 4.8 for patients with VAP and 9.2 for patients CAUTI. Excess crude mortality in ICUs was 30.9% for CLABSI, 14.5% for VAP and 17.6% for CAUTI.
Conclusion: DA-HAI rates in our ICUs from Ecuador are higher than United States CDC/NSHN rates and similar to INICC international rates.
The economic burden of nosocomial infections for hospitals: evidence from Germany.
Asegu L, Kitschen A, Neuwirth M, Sauerland D BMC Infect Dis. 2024; 24(1):1294.
PMID: 39538236 PMC: 11562106. DOI: 10.1186/s12879-024-10176-8.
Moradi S, Najafpour Z, Cheraghian B, Keliddar I, Mombeyni R Health Sci Rep. 2024; 7(11):e70168.
PMID: 39512247 PMC: 11540804. DOI: 10.1002/hsr2.70168.
Li X, Cai P, Zhong H, Yan C, Wen R Front Public Health. 2024; 12:1399067.
PMID: 39346583 PMC: 11427336. DOI: 10.3389/fpubh.2024.1399067.
Alwazzeh M, Alnimr A, Al Nassri S, Alwarthan S, Alhajri M, AlShehail B Antimicrob Resist Infect Control. 2023; 12(1):128.
PMID: 37981696 PMC: 10659071. DOI: 10.1186/s13756-023-01338-5.
Alotaibi N, Barri A, Somily A Cureus. 2023; 15(3):e35898.
PMID: 37033526 PMC: 10081389. DOI: 10.7759/cureus.35898.